Arrowhead Pharmaceuticals and Amgen will together work to develop and commercialize two drugs designed to treat cardiovascular disease, the companies said Thursday.
Under the terms of the agreements, Amgen will pay Arrowhead a combined $56.5 million—$35 million in cash, and the... Read more »
Startup creation firm Allied Minds announced a partnership Thursday with GE’s venture arm to jointly invest in promising technologies.
The deal speaks to broader trends in how companies get formed and funded beyond traditional means like venture capital and the public... Read more »
With public interest in artificial intelligence technologies on the rise, five of the world’s largest corporations—vying against each other in so many spheres—are banding together to support research on the ethical and societal issues raised by machines with increasingly human-like capabilities.... Read more »
San Antonio — For a researcher trying to turn their science into a business, sometimes the big issues—such as perfecting an intricate scientific process like gene editing—feels like a less daunting task than what might seem to be smaller stuff, like... Read more »
Gener8tor, a startup accelerator whose programs have taken place exclusively in Wisconsin up to this point, took a key step forward in its expansion into Minnesota this week.
The University of Minnesota’s technology transfer arm, known as the Office for... Read more »
[Corrected, 9/29/16, 4:24 p.m. See below.] Cancer immunotherapy has captured the medical world’s attention, knocking out a few types of cancer in a small portion of the most desperate patients. But it has bumped into many limitations.
Researcher Wendell... Read more »
Houston—Aging 2.0 now has a perch in the home of one of the world’s largest medical centers.
The San Francisco-based organization, focused on supporting innovation tailored to the needs of older adults, kicks off its Houston chapter today with... Read more »
To date, the studies Genocea Biosciences has run have not made clear how much better its experimental genital herpes vaccine is than a placebo at treating patients with the infection. Genocea is touting new results today that bolster its case for... Read more »
If Ginkgo Bioworks has its way, robots and software will someday handle most of the genetic engineering work currently performed by scientists sitting at lab benches.
Ginkgo is contributing to that shift. Today the synthetic biology company announced an expansion of... Read more »
The idea of using laboratory techniques to create food sounds like something out of science fiction—think of the food replicators depicted on Star Trek. But the concept of lab-grown food is gaining traction as entrepreneurs and scientists look for ways... Read more »
Success in the hyper-competitive mobile app industry takes endurance. App makers jockey for a coveted spot on our devices’ tiny screens, but few manage to keep our attention over the long haul.
One of those rare app companies with staying power... Read more »
Xconomy has brought together some of Boston’s top biotech founders, investors, and leaders for an evening of candid and interactive chats for our latest version of “Boston’s Life Science Disruptors.” On Oct. 20 at the Koch Institute for Integrative... Read more »
[Updated 9/29/16, see below] Several promising antipsychotic drugs have made it to late-stage clinical trials only to come up short. Today, you can add an experimental treatment from Intra-Cellular Therapies to the list.
Shares of New York-based Intra-Cellular (NASDAQ:... Read more »